Impact of systemic therapy on the serum vascular endothelial growth factor levels in patients with hepatocellular carcinoma after transarterial chemoembolization

Impact of systemic therapy on the serum vascular endothelial growth factor levels in patients with hepatocellular carcinoma after transarterial chemoembolization - Impact of systemic therapy on the serum vascular endothelial growth factor levels in patients with hepatocellular carcinoma after transarterial chemoembolization

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000053279

Enrollment

300

Registered

2024-01-05

Start date

2023-10-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatocellular carcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with unresectable advanced hepatocellular carcinoma (HCC) who are scheduled for Transarterial Chemoembolization

Exclusion criteria

Exclusion criteria: exclusion criterion 1. Child-Pugh C patients: 2. Patients with esophageal varices that may cause bleeding 3. Patients with gastrointestinal bleeding within 1 month 4. Patients who are pregnant, may be pregnant, or are breastfeeding 5. Patients with severe hypersensitivity to the components of this drug 6. Patients with severe heart failure or renal failure 7. Patients with malignant tumors other than hepatocellular carcinoma 8. Other patients unsuitable as subjects by the research director

Design outcomes

Primary

Measure	Time frame
Comparing the amount of change in VEGF levels before and after Transarterial Chemoembolization for each systemic drug therapy	—

Countries

Japan

Contacts

Public ContactHaruki Uojima

Kitasato University School of Medicine Department of Gastroenterology

kiruha@kitasato-u.ac.jp0427788111

Outcome results